Patents by Inventor Tobias A. Fuchs

Tobias A. Fuchs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNASE1-LIKE 3 AND ITS USE IN THERAPY
    Publication number: 20240374643
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Application
    Filed: May 8, 2024
    Publication date: November 14, 2024
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20240238388
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: October 16, 2023
    Publication date: July 18, 2024
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11840712
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 12, 2023
    Assignee: Neutrolis, Inc.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
    Patent number: 11819540
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 21, 2023
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11578314
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (DTL2), DNASE1-LIKE 3 Isoform 1 (DTL3), DNASE1-LIKE 3 Isoform 2 (DTL3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: February 14, 2023
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
    Patent number: 11510970
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: November 29, 2022
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Engineered human extracellular DNASE enzymes
    Patent number: 11352613
    Abstract: The present disclosure provides a library of engineered DNASE proteins (including DNASE1, DNASE1-LIKE 1, DNASE1-LIKE 2, DNASE1-LIKE 3, DNASE2A, DNASE2B) that allows to select drug candidates for developing therapeutics for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the selected DNase variant has improved properties, including properties amenable to clinical development, including manufacturing, toxicology, pharmacokinetic, and/or use in therapy.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: June 7, 2022
    Assignee: Neutrolis, Inc.
    Inventor: Tobias A. Fuchs
  • Methods of using DNASE1-like 3 in therapy
    Patent number: 11058724
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: July 13, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • DNase therapy for intravascular accumulation of extracellular DNA
    Patent number: 11046943
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • DNase therapy for intravascular accumulation of extracellular DNA
    Patent number: 11046942
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Manufacturing and engineering of DNASE enzymes for therapy
    Patent number: 10988746
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 27, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20210023183
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 28, 2021
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Engineered DNase enzymes and use in therapy
    Patent number: 10801019
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: October 13, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20200206321
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: February 27, 2020
    Publication date: July 2, 2020
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Engineered DNase enzymes and use in therapy
    Patent number: 10696956
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 30, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
    Patent number: 10617742
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries e.g., preventing transfusion-related acute lung injury (TRALI), by treating blood transfusion products with an anti-Neutrophil Extracellular Trap (NET) compound.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 14, 2020
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20170196945
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: March 30, 2017
    Publication date: July 13, 2017
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
    Patent number: 9642822
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: May 9, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20140199329
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 17, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas